JP2020507566A - ベンゾチオフェンエストロゲン受容体モジュレーター - Google Patents

ベンゾチオフェンエストロゲン受容体モジュレーター Download PDF

Info

Publication number
JP2020507566A
JP2020507566A JP2019542672A JP2019542672A JP2020507566A JP 2020507566 A JP2020507566 A JP 2020507566A JP 2019542672 A JP2019542672 A JP 2019542672A JP 2019542672 A JP2019542672 A JP 2019542672A JP 2020507566 A JP2020507566 A JP 2020507566A
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019542672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507566A5 (https=
Inventor
ジャイ コペランド ストラム
ジャイ コペランド ストラム
Original Assignee
ジー１ セラピューティクス， インコーポレイテッド
ジー１ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジー１ セラピューティクス， インコーポレイテッド, ジー１ セラピューティクス， インコーポレイテッド filed Critical ジー１ セラピューティクス， インコーポレイテッド
Publication of JP2020507566A publication Critical patent/JP2020507566A/ja
Publication of JP2020507566A5 publication Critical patent/JP2020507566A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019542672A 2017-02-10 2018-02-09 ベンゾチオフェンエストロゲン受容体モジュレーター Withdrawn JP2020507566A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762457643P 2017-02-10 2017-02-10
US62/457,643 2017-02-10
US201762460358P 2017-02-17 2017-02-17
US62/460,358 2017-02-17
US201862614279P 2018-01-05 2018-01-05
US62/614,279 2018-01-05
PCT/US2018/017668 WO2018148576A1 (en) 2017-02-10 2018-02-09 Benzothiophene estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JP2020507566A true JP2020507566A (ja) 2020-03-12
JP2020507566A5 JP2020507566A5 (https=) 2021-03-25

Family

ID=63106724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542672A Withdrawn JP2020507566A (ja) 2017-02-10 2018-02-09 ベンゾチオフェンエストロゲン受容体モジュレーター

Country Status (10)

Country Link
US (3) US10208011B2 (https=)
EP (1) EP3580223A4 (https=)
JP (1) JP2020507566A (https=)
KR (1) KR20190117582A (https=)
CN (1) CN110461853A (https=)
AU (1) AU2018217809A1 (https=)
CA (1) CA3052810A1 (https=)
IL (1) IL268319A (https=)
TW (1) TW201835064A (https=)
WO (1) WO2018148576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
CN112041307B (zh) * 2018-02-06 2024-02-09 伊利诺伊大学评议会 作为选择性雌激素受体降解剂的取代的苯并噻吩类似物
CN108203404A (zh) * 2018-03-02 2018-06-26 上海博邦医药科技有限公司 (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
EP4039331A4 (en) 2019-09-30 2024-01-17 Nippon Chemiphar Co., Ltd. Azepan derivative
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN113816892A (zh) * 2021-08-27 2021-12-21 安徽鼎旺医药有限公司 一种醋酸巴多昔芬的合成方法
CN113801094A (zh) * 2021-10-29 2021-12-17 中国药科大学 一种2-羰基苯并噻吩类化合物及其制备方法和用途
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
AU509682B2 (en) 1975-10-28 1980-05-22 Eli Lilly And Company 2-Aroyl-3-Phenylbenzothiophene Derivatives
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5834468A (en) 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
JP2001519349A (ja) 1997-10-03 2001-10-23 イーライ・リリー・アンド・カンパニー ベンゾチオフェン
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
US7091240B2 (en) 2000-03-10 2006-08-15 Oxigene, Inc. Tubulin binding ligands and corresponding prodrug constructs
AU2001271785A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of statins, estrogenic agents and optionally estrogens
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003986A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating breast disorders
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
AU7178301A (en) 2000-07-06 2002-01-21 American Home Prod Methods for increasing nitric oxide synthase activity
MXPA03000170A (es) 2000-07-06 2003-05-27 Wyeth Corp Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos.
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
ATE423122T1 (de) 2003-08-15 2009-03-15 Astrazeneca Ab Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
FR2862646B1 (fr) 2003-11-20 2006-02-24 Merck Sante Sas Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
AU2006206446A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AU2006212726C1 (en) 2005-02-14 2013-05-16 Bionomics Limited Novel tubulin polymerisation inhibitors
JP5315060B2 (ja) 2006-02-03 2013-10-16 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP1947085A1 (en) 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
BRPI0814532A2 (pt) 2007-07-25 2015-01-27 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação dos receptores de h3, e uso desses compostos para a preparação de medicamentos.
WO2010093578A1 (en) 2009-02-10 2010-08-19 Glaxo Group Limited Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
US8809382B2 (en) 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2819299A1 (en) 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP2809312A1 (en) 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2912033A4 (en) 2012-10-24 2016-09-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES
ES2774935T3 (es) 2012-10-24 2020-07-23 Univ Illinois Composiciones y métodos para tratar trastornos médicos relacionados con estrógeno
ES2671516T3 (es) * 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
WO2017056115A1 (en) 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
US9975856B2 (en) 2015-10-07 2018-05-22 Genentech, Inc. Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
WO2017072792A1 (en) 2015-10-27 2017-05-04 Sun Pharma Advanced Research Company Limited Novel heterocyclic antiestrogens
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
EA034994B1 (ru) 2016-02-15 2020-04-15 Санофи 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов

Also Published As

Publication number Publication date
US20200216406A1 (en) 2020-07-09
US20180230123A1 (en) 2018-08-16
CN110461853A (zh) 2019-11-15
US10633362B2 (en) 2020-04-28
KR20190117582A (ko) 2019-10-16
EP3580223A1 (en) 2019-12-18
US20190119243A1 (en) 2019-04-25
CA3052810A1 (en) 2018-08-16
WO2018148576A1 (en) 2018-08-16
AU2018217809A1 (en) 2019-08-22
EP3580223A4 (en) 2021-01-06
US10208011B2 (en) 2019-02-19
US10981887B2 (en) 2021-04-20
IL268319A (en) 2019-09-26
TW201835064A (zh) 2018-10-01

Similar Documents

Publication Publication Date Title
US10981887B2 (en) Benzothiophene estrogen receptor modulators
US12054469B2 (en) Benzothiophene-based selective estrogen receptor downregulator compounds
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
US20210171554A1 (en) Benzothiophene estrogen receptor modulators to treat medical disorders
TW202328101A (zh) 用於標靶降解brd9之經選擇的化合物
US10703747B2 (en) Benzothiophene-based selective mixed estrogen receptor downregulators
TW202208372A (zh) 用於治療醫療病症之周期蛋白依賴型激酶抑制性化合物
JPWO2018186366A1 (ja) 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
CN120548178A (zh) 突变体braf降解剂的晶型及其制备方法
BR112019027967A2 (pt) forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina
HK1262188B (en) Benzothiophene-based selective estrogen receptor downregulators
HK1262188A1 (en) Benzothiophene-based selective estrogen receptor downregulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20211126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211202